UBS Group AG has filed its Form 13F-HR for the third quarter of 2026, disclosing the equity securities held by its investment advisory business, UBS Asset Management Americas LLC. The filing, dated November 10, 2026, lists a total of 242,777 equity securities held across 61 distinct positions.
The portfolio includes a mix of large-cap blue-chip companies and specialized exchange-traded funds (ETFs). Significant holdings include 3M Company, for which UBS holds 301,640,234 shares, and Abbott Laboratories, with 293,379,523 shares. The filing also details positions in ABBVIE Inc., with 1,622,197,282 shares, and 10X Genomics Inc., with 4,297,611 shares.
UBS has disclosed positions in various ETFs, including the 2023 ETF Series Trust Atlas American Fund, the 21Shares Dogecoin ETF, and the 21Shares Ethereum Staking ETF. The filing also lists several Special Purpose Acquisition Companies (SPACs), such as 1RT Acquisition Corp. and AA Mission Acquisition Corp.
